ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

ENDO-RESTORATIVE RELATIONSHIP

Nasser Abdullah Alshehri, Albatool Hassan Baroom, Jassem Abdullah Al Mubarak, sara Sulaiman al rashdi, Heba Ibrahim Mubaraki, Abeya Ghalib Mardini, Samirah hashim jabir, Ragad abdulrhman alshehri, Nesmah Nazeer Bahrawi ,Mohammed Samir Al-Janoubi

Introduction: The primary goal of endodontic therapy is to prevent and treat apical periodontitis. Proper cleaning and shaping of canals, irrigation, and coronal seal are essential to achieving this goal while restorative dentistry aims to restore teeth to comfort, function and aesthetics. The relationship between restorative dentistry and endodontic has been established although the concepts related to treatment plans is ambivalent. With the advent of advanced dentistry, emphasis should be given on restorability of teeth before endodontic treatment. The aim of work: The review focuses on the decision in treatment planning and endodontic-restorative interface to best restore teeth following endodontic treatment. Methodology: We conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, January 1985, through February 2017. The following search terms were used: Endodontic treatment, Restorative dentistry, Post and Core Conclusion: With the emergence of advanced dentistry such as implants, more emphasis is given on long-term outcome of treatment thus evaluation of restorability of teeth before endodontic treatment is important. The treatment is not well served if tooth fails despite successful endodontic treatment. Keywords: Endodontic treatment, Restorative dentistry, Post and Core.

FULL TEXT

CAN EJACULATORY DYSFUNCTION BE RECOVERED BY LOW DOSE TAMSULOSIN WHILE TREATING SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA?

Mohamed G. Soliman, Ahmed A. Al-Khalifah, Ali H. Al-Khalifah, Ali R. Al-Amer, Ali S. Al-Badan, 6brahim F. Mutaki

Purpose: To evaluate the use of low dose Tamsulosin in relieving lower urinary tract symptoms related to benign prostatic symptoms as a trial to increase the drug safety ( in terms of reducing the drug full dose side effects especially retrograde ejaculation) while maintaining its efficacy in relieving the patients' symptoms. Material and Methods: This Prospective study was conducted in King Faisal University polyclinic between November 2013 and March 2014. Patients enrolled in this study were suffering from Lower urinary tract symptoms due to benign prostatic hyperplasia and were receiving 0.4 mg Tamsulosin for variable period and was complaining of ejaculatory dysfunction. Base line assessment involved medical history with evaluation of ejaculatory function, IPSS, abdominopelvic ultrasound with estimation of postvoid residual urine (PVR) and quality of life questionnaire. The patients were excluded whenever there is any significant aggravation of their symptom. During the course of this study, 0.2 mg Tamsulosin was given to patients and they were assessed by the same tools of base line assessment at the first and third month of the study. Drug compliance and adverse events were also recorded in all patients. Results: Before we started our treatment with the low dose, twenty one patients had mean IPSS of 7.00 ± 0.948 and mean residual volume of 92.38 ± 20.47 ml. At first month follow up, the mean IPSS and the mean residual volume became 7.47 ± 0.67 and 104.76 ± 21.82 ml respectively with a statistically significant difference as compared with that of the baseline (p-value <0.05). Out of 21 patients, 16 (76.2%) patients reported no ejaculation at all and 5 (23.8%) patients reported low ejaculatory volume. After treatment with low dose Tamsulosin i.e. 0.2 mg, out of 16 patients with no ejaculation, 12 (75%) had recovered and out of the 5 patients who reported low ejaculatory volume, 3 (60%) patients reported increased ejaculatory volume. All patients with improved ejaculatory function were fully satisfied as measured by quality of life score and want to continue on the low dose. None of our patients showed adverse effects with the low dose. Conclusion: For patients complaining from LUTS due to BPH, low dose Tamsulosin (0.2 mg/day) shows potential advantage for patients with bothering ejaculatory dysfunction. In spite of the significant change in IPSS after administration of the low-dose, most of patients show higher overall satisfaction rate as compared to the standard dose (0.4mg/day). A prospective study on a large scale is still needed to confirm our result. Key words: Prostate, Prostatic Hyperplasia, Tamsulosin, Ejaculation, Erectile dysfunction, Lower urinary tract symptoms

FULL TEXT